Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Sep;52(6):1094-1095.
doi: 10.1111/apt.16000.

Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune-tolerant phase-authors' reply

Han Ah Lee  1 , Seung Up Kim  2   3
Affiliations
Comment

Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune-tolerant phase-authors' reply

Han Ah Lee et al. Aliment Pharmacol Ther. 2020 Sep.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Wan B, Chen R, Lin H, et al. Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune-tolerant phase. Aliment Pharmacol Ther. 2020;52:1093.
    1. Lee HA, Lee HW, Kim IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther. 2020;52:196-204.
    1. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862-873.
    1. Kim DS, Jeon MY, Lee HW, et al. Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. Clin Mol Hepatol. 2019;25:283-293.
    1. Zhu LY, Wang YG, Wei LQ, Zhou J, Dai WJ, Zhang XY. The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease. Drug Des Devel Ther. 2016;10:2739-2744.

Substances

LinkOut - more resources